GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IR Biosciences Holdings Inc (GREY:IRBS) » Definitions » Price-to-Owner-Earnings

IR Biosciences Holdings (IR Biosciences Holdings) Price-to-Owner-Earnings : (As of Jun. 21, 2024)


View and export this data going back to . Start your Free Trial

What is IR Biosciences Holdings Price-to-Owner-Earnings?

As of today (2024-06-21), IR Biosciences Holdings's share price is $6.0E-5. IR Biosciences Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for IR Biosciences Holdings's Price-to-Owner-Earnings or its related term are showing as below:


IRBS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.85
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-21), IR Biosciences Holdings's share price is $6.0E-5. IR Biosciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2010 was $-0.35. Therefore, IR Biosciences Holdings's PE Ratio for today is At Loss.

As of today (2024-06-21), IR Biosciences Holdings's share price is $6.0E-5. IR Biosciences Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.30. Therefore, IR Biosciences Holdings's PE Ratio without NRI for today is At Loss.


IR Biosciences Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for IR Biosciences Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IR Biosciences Holdings Price-to-Owner-Earnings Chart

IR Biosciences Holdings Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IR Biosciences Holdings Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IR Biosciences Holdings's Price-to-Owner-Earnings

For the Biotechnology subindustry, IR Biosciences Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IR Biosciences Holdings's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IR Biosciences Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where IR Biosciences Holdings's Price-to-Owner-Earnings falls into.



IR Biosciences Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

IR Biosciences Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=6.0E-5/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IR Biosciences Holdings  (GREY:IRBS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


IR Biosciences Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of IR Biosciences Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


IR Biosciences Holdings (IR Biosciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
8777 E. Via De Ventura, Suite 280, Scottsdale, AZ, USA, 85258
IR Biosciences Holdings Inc is a development-stage biotechnology company engaged in the research & development of potential drug candidate, Homspera and its derivatives, Radilex and Viprovex through its subsidiary, ImmuneRegen BioSciences, Inc. It is engaged in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia.

IR Biosciences Holdings (IR Biosciences Holdings) Headlines

No Headlines